Zhang Peace Team: Probiotic-assisted treatment of IBS can relieve symptoms and reduce inflammation

。1. IBS patients were randomly divided into probiotic group (24 cases) and control group (21 cases), respectively, to receive routine treatment with or without probiotics, 2. After 28 days of intervention, compared with the control group, probiotic group IBS symptom severity score, serum IL-6 and TNF-α were significantly reduced; 3. Probiotics significantly reduced some of the strains that can worsen IBS, such as mycobacterium genus, Bacillus Ethyrobacteria, Bacillus citric acid genus; 4. Some beneficial genus in the control group decreased significantly, including Bifidobacteria genus, mycobacterium genus, Dorsey genus and butythrobacteria genusthe editor-in- that irritable bowel syndrome (IBS) is a common functional bowel disease. A recent study by Zhang Peace Team at Inner Mongolia Agricultural University in European Journal of Nutrition evaluated probiotic products (including Cheese Cheese Lactobacillus Zhang, Plant Lactobacillus P-8 and Animal Bifidobacteria Milk Subsection V9) as an auxiliary treatment for IBS For the results of the program, it was found that one month of probiotic intervention significantly reduced the patient's symptom score and reduced the level of serum inflammatory factors (IL-6 and TNF-α), while the improvement of IBS symptoms was associated with probiotic regulation of the bacteria.the original information and link origin of this study, as well as relevant interpretation and comment articles. Readers and friends are welcome to recommend!。 European Journal of nutrition(IF:4.664) Adjunctive treatment with probiotics partially alleviates symptoms and reduces in patients with irritableel syndrome
probiotic-assisted treatment partially relieves symptoms and reduces inflammation in IBS patients


10.1007/s00394-020-02437-4
11-22, Article
Abstract: Purpose: Irritable bowel syndrome (IBS) is a functional bowel disorder. This study aimed to assess the effect of a probiotic product (containing Lactobacillus casei Zhang, Lactobacillus plantarum P-8, and Bifdobacterium animalis subsp. lactis V9) as an adjunct to a routine regimen in IBS management.
Methods: Forty-five patients with IBS were randomized into the probiotic (n = 24) and control (n = 21) groups, receiving the routine regimen with or without probiotics for 28 days, respectively. Serum and fecal samples were collected and analyzed.
Results: The IBS-symptom severity score (P < 0.01), serum levels of IL-6 (P < 0.01) and TNF-α (P < 0.001) were significantly lower in the probiotic group than the control group at day 28. The probiotic adjunctive treatment resulted in significant decreases in some bacterial genera that worsen IBS, such as Bacteroides (P < 0.01), Escherichia (P < 0.05), and Citrobacter (P < 0.05), significant decreases were also observed in some beneficial genera in the control group, including Bifidobacterium (P < 0.05), Eubacterium (P < 0.05), Dorea (P < 0.01), and Butyricicoccus (P < 0.05。 ). Furthermore, significant correlations were found between some monitored parameters and compositional changes in the fecal microbiota, suggesting that the clinical improvement of IBS was likely associated with gut microbiota modulation. The enterotype analysis revealed that the initial fecal microbiota composition could influence clinical outcomes.
Conclusions: The adjunctive use of probiotics with a routine regimen showed additional clinical effectiveness compared to the routine regimen alone in managing IBS. A pretreatment gut microbiome analysis might help tailor a personalized probiotic regimen to optimize treatment effects.。 First Authors:
Haiyan Xu
Correspondence Authors:
Lai-Yu Kwok,Heping Zhang
All Authors:
Haiyan Xu,Chen Ma,Feiyan Zhao,Ping Chen,Yahua Liu,Zhihong Sun,Lihong Cui,Lai-Yu Kwok,Heping Zhang。